This is in line with a study performed in 95 breast cancer patients receiving the same compound combination, which observed an odds ratio of 5.29 (95% CI: 2.10–13.33) in patients with <75 mL/min/1.73 m2 for experiencing an episode of neutropenic fever with hospital admission, treatment delay, dose adjustment due to toxicity, or the need for granulocyte colony-stimulating factor (G-CSF) [20]. This evidence concerns the gene CSF3 and breast cancer.